People are asking questions and seeking answers to address the burden of kidney cancer worldwide
AMSTERDAM-Tuesday, June 20th 2017 [ ME NewsWire ]
(BUSINESS WIRE)-- Kidney cancer is a silent disease that’s on the rise. The global incidence of kidney cancer is predicted to increase by a shocking 22 percent by 2020. Explanations are incomplete, but include risk factors such as aging, obesity, high blood pressure and smoking.
The lack of answers is why the International Kidney Cancer Coalition (IKCC) and kidney cancer organisations worldwide are marking the first-ever World Kidney Cancer Q&A Day. On June 22, patients, carers, health care professionals and local organisations will be asking questions and seeking answers:
What explains the varying incidence of kidney cancer worldwide? High rates incidence are seen in northern and eastern Europe, North America and Australia, with the highest rates estimated in the Czech Republic?
How can we addres
...
Read more »
|
GENEVA -Tuesday, June 20th 2017 [ ME NewsWire ]
(BUSINESS WIRE)-- Masimo (NASDAQ: MASI) announced today the findings of an abstract presented at Euroanaesthesia 2017 in Geneva, Switzerland. In the study, researchers at University Medical Center Groningen, Netherlands, compared original and Next Generation versions of Masimo Patient State Index (PSi, a processed EEG parameter related to the effect of anesthetic agents) during Masimo SedLine® brain function monitoring of patients under propofol and sevoflurane anesthesia.1
SedLine brain function monitoring features four simultaneous EEG leads to enable continuous assessment of both sides of the brain, four EEG waveforms, a Density Spectral Array (DSA, an easy-to-interpret, high-resolution display of bi-hemispheric activity and EEG power), and PSi. Next Generation SedLine enhances PSi to make it less susceptible to electromyographic (EMG) interference and to improve its performance in low-power EEG cases.
In
...
Read more »
Views:
180
|
Added by:
africa-live
|
Date:
06.21.2017
|
|
PARIS & DARMSTADT, Germany-Thursday, June 15th 2017 [ ME NewsWire ]
(BUSINESS WIRE)-- Worldwide Innovative Network in Personalized Cancer Medicine - WIN Consortium proudly announces today that Merck, which operates its biopharmaceutical business as EMD Serono in the U.S. and Canada, becomes a member of the WIN Consortium. WIN is a network of 40 academic institutions and industries across the globe, focusing on new generation biomarker-driven therapeutic clinical trials and biomarker discovery programs conducted worldwide, aiming to significantly impact the survival of cancer patients. Merck reinforces WIN’s pharmaceutical industry membership. WIN’s global collaborative research strategy will be presented at the WIN2017 Symposium in Paris, France, on 26-27 June.
Merck’s strong corporate commitment to the development of drugs using a precision medicine approach, coupled with the company’s wide breadth of experience in the development of onco
...
Read more »
| |